1.16MMarket Cap-128P/E (TTM)
1.7800High1.6100Low38.60KVolume1.6900Open1.7253Pre Close64.62KTurnover5.71%Turnover RatioLossP/E (Static)693.18KShares21.600052wk High0.31P/B1.14MFloat Cap1.610052wk Low--Dividend TTM676.44KShs Float1668.0000Historical High--Div YieldTTM9.85%Amplitude1.6100Historical Low1.6740Avg Price1Lot Size
Dermata Therapeutics Stock Forum
Dermata Announces Achievement of 50% Enrollment in Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne
Dermata Therapeutics (Nasdaq: DRMA) has announced 50% enrollment in its pivotal Phase 3 STAR-1 clinical trial for DMT310, a novel once-weekly topical treatment for moderate-to-severe acne. The study, which began in December 2023, is the first of two Phase 3 trials aimed at supporting a new drug application (NDA) for DMT310. Topline results are expected in Q...
Larger Image: tradingview.com...
$Dermata Therapeutics(DRMA.US)$
omg. this counter is expecting bankruptcy or what?
Bet this will jump out of the blue!!! holding…..
No comment yet